TEL AVIV, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or...
First-in-Class CCL24 Neutralizing Antibody CM-101 Demonstrated a Favorable Safety Profile and Was Generally...
—Proteomic Analysis of Patient Samples Further Confirms that CCL24 is Associated with Primary Sclerosing...
—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity...
TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a...
─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2...
TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a...
TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a...
TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a...
—Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.